Pembrolizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Pembrolizumab and local guidelines before prescribing.
Mechanism
PD-1 inhibitor restoring T-cell antitumour activity.
Uses
Melanoma, non-small-cell lung cancer, head and neck, urothelial and other cancers.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Immune-related colitis, pneumonitis, hepatitis, endocrinopathies, rash, fatigue.
Interactions
Immunosuppressants reduce effect.
Contraindications and cautions
Autoimmune disease caution
Monitoring
TFT, LFT, cortisol, glucose, U&E
Pregnancy and breastfeeding
Avoid; contraception during and after
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive; steroids for immune toxicity
Special advice
Same immune-related toxicity pathway as other checkpoint inhibitors; check TFT and cortisol; steroids early for moderate toxicity.
More from the textbook: uses, cautions and other points
- An immune-related adverse event of PD-1, PD-L1 and CTLA-4 inhibitors (e.g. pembrolizumab, nivolumab, ipilimumab). Uncommon (about 1%) but with mortality of up to a quarter to a half in fulminant cases.
Cardiology: Cardiomyopathies - Mechanism: Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, ipilimumab) release the brakes on the immune system. As well as attacking the cancer, they can cause immune-related adverse events in almost any organ - at any time, even months after stopping.
Respiratory: Lung Cancer - Pembrolizumab (and other checkpoint inhibitors) | Immunotherapy - alone if PD-L1 is 50% or more, or with chemotherapy. Immune-related adverse events - treat with steroids via acute oncology.
Respiratory: Lung Cancer - Immune checkpoint inhibitors (pembrolizumab, nivolumab) | Immune pneumonitis - urgent assessment; steroids
Respiratory: Anatomy, Physiology and Pharmacology - Immune checkpoint inhibitors (pembrolizumab, nivolumab) - immune-related pneumonitis.
Respiratory: Interstitial Lung Disease - No targetable mutation: Immunotherapy (checkpoint inhibitors such as pembrolizumab ), alone if PD-L1 is high (50% or more), or with platinum chemotherapy.
Respiratory: Lung Cancer - On pembrolizumab, fatigue, headache, low cortisol and low ACTH | Immunotherapy-induced hypophysitis
Respiratory: Lung Cancer - Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) | Thyroiditis, hypophysitis (ACTH deficiency - headache, fatigue), adrenalitis, sudden type 1 diabetes and DKA
Endocrine: Anatomy Physiology and Pharmacology
Where it is discussed in the book
- Cardiology: Cardiomyopathies (1 mention)
- Respiratory: Anatomy, Physiology and Pharmacology (1 mention)
- Respiratory: Interstitial Lung Disease (1 mention)
- Respiratory: Lung Cancer (4 mentions)
- Endocrine: Anatomy Physiology and Pharmacology (2 mentions)
- Endocrinology: Diabetes (1 mention)
- Gastroenterology: Bowel Disorders (1 mention)
- Gastroenterology: Inflammatory Bowel Disease (1 mention)
- Gastroenterology: Pancreas and Biliary (1 mention)
- Haematology: Myeloma and Lymphoma (1 mention)
- Oncology: Principles (4 mentions)
- Oncology: Emergencies (1 mention)
- Oncology: Urology and Genital cancers (4 mentions)
- Oncology: Breast and Gynae Cancers (6 mentions)
- Oncology: Skin Cancer (2 mentions)
- Dermatology: Skin lesions and skin cancer (3 mentions)
- Rheumatology: Emergencies, pregnancy and other systemic diseases (2 mentions)
- ENT: Neck lumps and cancer (3 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (3 mentions)
- Clinical Genetics: Cancer genetics and inherited cardiovascular conditions (1 mention)
- Integrated cardiology chapter (1 mention)
- Integrated respiratory chapter (5 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (2 mentions)